Rhythm Biosciences soars on meeting primary endpoint for cancer detection test

Rhythm Biosciences

04/04/2022 06:18

** Shares of Rhythm Biosciences  RHY.AX  jump as much as
22.5% to A$1.80, set for best session since January 2021, if
gains hold
    ** The cancer diagnostic co announces achievement of primary
endpoint for ColoSTAT, a blood test used for detection of
colorectal cancer  urn:newsml:reuters.com:*:nASX33zzHM
    ** Says ColoSTAT was found 35% more accurate than the market
standard Faecal Immunochemical Test (FIT) for detecting cancer
    ** RHY hits highest since Dec. 14, 2021 
    ** More than 700,000 shares change hands, compared with the
30-day average volume of about 176,000 shares
    ** Stock on track for sixth straight session of gains 
    ** Stock has fallen 5.2% this year, as of last close

 (Reporting by Jaskiran Singh in Bengaluru)
 ((Jaskiran.Singh@thomsonreuters.com;))